| Current perspectives on statins. | |
| | |
MedLine Citation:
|
PMID: 10637210 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Statins (HMG-CoA reductase inhibitors) are used widely for the treatment of hypercholesterolemia. They inhibit HMG-CoA reductase competitively, reduce LDL levels more than other cholesterol-lowering drugs, and lower triglyceride levels in hypertriglyceridemic patients. Statins are well tolerated and have an excellent safety record. Clinical trials in patients with and without coronary heart disease and with and without high cholesterol have demonstrated consistently that statins reduce the relative risk of major coronary events by approximately 30% and produce a greater absolute benefit in patients with higher baseline risk. Proposed mechanisms include favorable effects on plasma lipoproteins, endothelial function, plaque architecture and stability, thrombosis, and inflammation. Mechanisms independent of LDL lowering may play an important role in the clinical benefits conferred by these drugs and may ultimately broaden their indication from lipid-lowering to antiatherogenic agents. |
| | |
Authors:
|
D J Maron; S Fazio; M F Linton |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: Circulation Volume: 101 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2000 Jan |
Date Detail:
|
Created Date: 2000-02-01 Completed Date: 2000-02-01 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 207-13 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University, School of Medicine, Nashville, TN 37232-6300 , USA. david.maron@mcmail.vanderbilt.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
therapeutic use Cardiology / trends* Clinical Trials as Topic Drug Therapy, Combination Endothelium, Vascular / drug effects, physiopathology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects, pharmacology, therapeutic use* Hypercholesterolemia / drug therapy*, prevention & control Practice Guidelines as Topic |
| Grant Support | |
ID/Acronym/Agency:
|
HL-53989/HL/NHLBI NIH HHS; HL-57986/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling.
Next Document: New structural motifs on the chymotrypsin fold and their potential roles in complement factor B.